Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs061250043) titled 'Clinical trial of nasal HB vaccine for liver transplanted patients' on Aug. 5.
Study Type: Interventional
Study Design:
single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
Primary Sponsor: Hiasa Yoichi
Condition:
Liver transplantation due to HBV infection
D016031
Intervention:
CVP-NASVAC is administrated via nose total 3 times in every 2 weeks. Additional dose of CVP-NASVAC is administrated in regular medical visits. HBIG injection will be skipped, if anti-HBs titer is lower than 200 mIU/mL in regular visits.
Recruitment Status: Recruiting
Phase: 2
D...